Search

Your search keyword '"T, Hanada"' showing total 664 results
Start Over Author "T, Hanada"
664 results on '"T, Hanada"'

654. Severe aplastic anaemia treated with anti-lymphocyte globulin. The relationship between clinical course and erythroid colony suppression by T cells.

Author

Hanada T, Abe T, Fukao K, Jogamoto M, and Takita H

Subjects
Anemia, Aplastic blood, Antilymphocyte Serum pharmacology, Bone Marrow Cells, Cells, Cultured, Child, Colony-Forming Units Assay, Female, Humans, Immune Tolerance, Immunosuppressive Agents pharmacology, T-Lymphocytes immunology, Anemia, Aplastic therapy, Antilymphocyte Serum therapeutic use, Erythropoiesis drug effects, Immunosuppressive Agents therapeutic use
Abstract

A 6-year-old girl with severe aplastic anaemia improved promptly after treatment with anti-human lymphocyte globulin (ALG). Blood T lymphocytes were proved to have a suppressive effect on erythroid colony formation. ALG was administered intravenously at a dose of 15 mg/kg/d for 5 d. By the 14th d she showed a prompt increase in the reticulocyte count. Within the next 2 weeks slight increase of the platelet count was observed while the neutrophil count remained unchanged. The suppressive effect of T cells on erythroid colony formation weakened when the reticulocyte count exceeded 100 X 10(9)/l. About 4 months after administration of ALG, a decreased reticulocyte count was observed along with frequent nasal bleeding. Again the T cells exhibited a suppressive effect on erythroid colony formation. The results of serial co-culture studies revealed a close correlation between the T-cell suppressive effect on erythroid colony formation and reticulocyte response. The findings suggest an immune-mediated mechanism for the haematopoietic disorder in this patient.

Published
1982

656. [A phase II study of Futraful suppository in head and neck cancer].

Author

Ohyama M, Matsumura M, Katsuta K, Nobori T, Furuta S, Matsunaga S, Uchizono A, Hanada T, Moriyama I, and Kamachi S

Subjects
Aged, Anorexia chemically induced, Carcinoma, Squamous Cell drug therapy, Dose-Response Relationship, Drug, Drug Evaluation, Female, Humans, Male, Maxillary Sinus Neoplasms drug therapy, Middle Aged, Nausea chemically induced, Remission Induction, Suppositories, Tegafur administration & dosage, Tegafur adverse effects, Vomiting chemically induced, Head and Neck Neoplasms drug therapy, Tegafur therapeutic use
Abstract

A phase II study of FT-207 suppository (Futraful Suppository) for head and neck cancer was conducted at the Kagoshima University Hospital Dept. of Otorhinolaryngology and its 6 affiliated hospitals. Forty cases with head and neck cancer were entered in the trial, of which 37 were perfectly evaluable. Partial response (PR) (16.7%) was achieved in one of 6 patients with maxillary cancer, in 2 of 9 cases with oral cancer (22.2%), in one of 7 with laryngeal cancer (14.3%), in 3 of 13 with pharyngeal cancer, while 2 of the same 13 achieved a complete response (CR) (38.5%), for a total response rate of 24.3%. FT-207 suppository was continuously administered as standard, at a dose of 750 mg each twice daily, or 1,500 mg/day. The response rate was dose-dependent; 2 CR cases with a total dose of 105 g for administration over a total period of more than 150 days. Adverse effects appearing in 35.0% of the overall were mainly anorexia, nausea and vomiting; none of them, however, were serious.

Published
1988

659. [A case of pure red cell aplasia following hepatitis A].

Author

Tomiyama J, Kudou H, Adachi Y, Kinugasa K, and Hanada T

Subjects
Adult, Hematologic Tests, Humans, Male, Red-Cell Aplasia, Pure blood, Red-Cell Aplasia, Pure diagnosis, Hepatitis A complications, Red-Cell Aplasia, Pure etiology
Published
1987

Catalog

Books, media, physical & digital resources
See catalog results